Waljit Dhillo is a Professor in Endocrinology & Metabolism, Consultant Endocrinologist and an NIHR Research Professor. He is Head of the Section Endocrinology and Investigative Medicine at Imperial College London.
He completed his medical training at St Bartholomew’s Hospital Medical School, University of London in 1994. During this time he also completed an Intercalated BSc in Biochemistry (awarded First Class Honours) funded by the Medical Research Council. He then completed his general medical training in London Hospitals. In 1997 he joined the North West Thames Rotation in Diabetes and Endocrinology as a Specialist Registrar. During this time he completed a PhD on the area of novel neuropeptides regulating appetite as a Wellcome Trust Clinical Training Fellow at Imperial College with Professor Sir Steve Bloom. In 2004 he was awarded a National Institute for Health Research (NIHR) Clinician Scientist Fellowship and appointed Clinical Senior Lecturer & Consultant in Diabetes & Endocrinology at Imperial College London. Following this he was awarded an NIHR Career Development Fellowship and promoted to Reader in 2009. In 2011 he was promoted to Professor in Endocrinology & Metabolism. In 2015 Professor Dhillo was awarded a prestigious NIHR Research Professorship.
Professor Dhillo’s research investigates novel aspects of endocrine control of obesity and reproductive function.
His research has focused on understanding the neuroendocrine mechanisms which are important in the regulation of food intake. The regulation of body weight is complex and requires control of both food intake and energy expenditure. Gut hormones can powerfully reduce appetite and increase energy expenditure. Professor Dhillo's research investigates the mechanisms by which gut hormones mediate their effect. Recently he has shown that administration of gut hormones to human volunteers can alter neuronal activity in brain reward areas which control food intake (http://www.guardian.co.uk/science/2011/sep/11/obesity-food-appetite-suppressant). He was awarded the Royal College of Physicians Linacre Medal for this work. These findings have identified CNS pathways which have potential as novel targets for the development of anti-obesity drugs.
Professor Dhillo’s recent translational research has identified the novel hormone kisspeptin as a potential novel therapy for infertility. Professor Dhillo has carried out the ‘first time into human’ studies of kisspeptin. He has shown that kisspeptin potently stimulates reproductive hormone release in human male and female volunteers. This work was awarded the American Endocrine Society Award for Excellence in Clinical Research and the British Society for Neuroscience Investigator Prize. Professor Dhillo has also shown that kisspeptin administration potently increased reproductive hormone release in women with infertility due to hypothalamic amenorrhea (http://news.bbc.co.uk/1/hi/health/7945600.stm). Recently Professor Dhillo has shown for the first time in women with infertility that kisspeptin can be used safely and effectively in IVF treatment (http://www.bbc.co.uk/news/health-22935211). He was been awarded the Royal College of Physicians Goulstonian Lectureship (2010) and the Society for Endocrinology Medal (2015) for this work.
Professor Dhillo is passionate about supporting clinical academic training. He has been Head of training for all Imperial College Academic Clinical Fellows and Clinical Lecturers (since 2005). He has been Training Lead for Imperial College Biomedical Research Centre since 2013. In 2015 Professor Dhillo was appointed National Training Lead for NIHR Infrastructure overseeing and integrating doctoral training in 40 UK centres (>400 PhD students in programme across BRCs) and providing leadership for the 47 local training leads.
et al., 2017, Using kisspeptin to assess GnRH function in an unusual case of primary amenorrhoea., Endocrinol Diabetes Metab Case Rep, Vol:2017, ISSN:2052-0573
et al., 2017, Thermal imaging is a non-invasive alternative to PET-CT for measurement of brown adipose tissue activity in humans., J Nucl Med
et al., 2017, A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial, Human Reproduction, Vol:32, ISSN:0268-1161, Pages:1915-1924
Wernig F, Jayasena CN, Dhillo WS, 2017, Carcinoid syndrome and neuroendocrine tumours, Medicine (united Kingdom), Vol:45, ISSN:1357-3039, Pages:543-546
et al., 2017, Kisspeptin Is a Novel Regulator of Human Fetal Adrenocortical Development and Function: A Finding With Important Implications for the Human Fetoplacental Unit, Journal of Clinical Endocrinology & Metabolism, Vol:102, ISSN:0021-972X, Pages:3349-3359